Jonathan Lourie, a partner at Duane Morris LLP, advises companies, institutions, and individuals in the life sciences industry on financing, licensing, collaborations, and M&A. Lourie represents both U.S. and international biotechnology and medical device companies and research institutions in transactions such as venture financings, M&A, joint ventures, and technology licensing.
Legal 500 Editorial commentary
Phone
+1 857 488 4260
Email
Profile

Accolades

Boston Elite

Profile

Position

Partner

Career

Jonathan Lourie represents technology, science-based, and other companies and individuals around the world in joint ventures, technology transfer, mergers and acquisitions, venture capital, international law and securities law. Mr. Lourie's experience includes representing research tool and medical device companies in transactions involving such collaborations as vaccines, drug delivery technologies, therapeutics, diagnostics, blood products, cardiology, antimicrobials, genomics and research tool technologies. He also advises companies using artificial intelligence with due diligence, financing and licensing issues.

Mr. Lourie also represents software games and interactive media companies in a number of matters, including project development transactions, startups, and early- and late-stage financings and acquisitions. He is regularly involved in licensing research institution technologies to private companies for both companies and research institutions. Mr. Lourie also represents clients in outsourcing, enterprise software and IT integration in all transactions, including acquisitions and contracts. He represents specialized lenders in loan, project finance and other transactions in the food and agricultural industries.

Mr. Lourie is a magna cum laude graduate of Syracuse University College of Law, where he was senior lead articles editor for the Law Review, and a graduate of McGill University with a B.Sc. in Psychobiology.

Content supplied by Duane Morris LLP

Key clients

  • Anellotech, Inc.
  • Ology Bioservices, Inc.

Work highlights

Represented Ology Bioservices, Inc., a 300 employee drugs and biologics CDMO, in its sale to Resilience (National Resilience), along with as more than 200,000 square feet of manufacturing and office space.